ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1022

Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis

Walter P Maksymowych1, Anna Hadsbjerg2, Mikkel Østergaard3, Raphael Micheroli4, Susanne J. Pedersen5, Adrian Ciurea6, Nora Vladimirova2, Michael Nissen7, Kristyna Bubova8, Stephanie Wichuk9, Manouk de Hooge10, Ashish J Mathew11, Karlo Pintaric12, Monika gregova13, Ziga Snoj12, Marie Wetterslev14, Karel Gorican15, Joel Paschke16, Iris Eshed17 and Robert G Lambert9, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Copenhagen Center for Arthritis Research, Copenhagen, Denmark, 3Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 4University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, 5Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 6University Hospital Zurich, Zürich, Switzerland, 7Hopitaux Universitaires de Genève, Geneva, Switzerland, 8First Faculty of Medicine, Charles University,, Prague, Czech Republic, 9University of Alberta, Edmonton, AB, Canada, 10Ghent University Hospital, Luxembourg, Luxembourg, 11Rigshospitalet, Copenhagen, Denmark, 12Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 13Institue of Rheumatology, Prague, 14Rigshospitalet, Copenhagen, Glostrup, Denmark, 15MSK radiology unit, Radiology section – Diagnostic department, Geneva University Hospitals, Geneva, Switzerland, 16CARE Arthritis LTD, Edmonton, AB, Canada, 17Sheba Medical Center, Tel Aviv, Israel

Meeting: ACR Convergence 2022

Keywords: Magnetic resonance imaging (MRI), spondyloarthritis, Spondyloarthropathies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Quantification of inflammatory and structural lesions in the sacroiliac joints (SIJ) on MRI scans from patients with axial spondyloarthritis (axSpA) has a growing list of applications, especially for clinical trials. It is therefore essential that knowledge transfer tools are made available that can ensure understanding of scoring methodologies and enable remote training of readers across the globe so that they can reliably perform assessments. The web-based Spondyloarthritis Research Consortium of Canada (SPARCC) real-time iterative calibration (RETIC) modules for scoring inflammatory and structural MRI lesions in axSpA have been created by SPARCC developers to enable remote training of readers to appropriately use the SPARCC MRI inflammation and structural damage instruments and to attain adequate scoring proficiency. We aimed to test the performance of these modules in enhancing scoring proficiency in comparison to SPARCC developer gold standard.

Methods: The SPARCCRETIC SIJ inflammation and structural damage modules are each comprised of 50 DICOM axSpA cases with baseline and follow up scans and an online scoring interface based on SIJ quadrants. Continuous visual real-time feedback regarding concordance/discordance of scoring per SIJ quadrant with expert readers is provided by a color-coding scheme. Reliability is assessed in real-time by intra-class correlation coefficient (ICC), ICC data being provided every 10 cases, which are scored until proficiency targets for ICC are attained. Participants (n=15) from the EuroSpA Imaging project were randomized, stratified by reader expertise in scoring with SPARCC, to one of two reader training strategies (A and B) that each comprised 3 stages: A. 1. Review of original SPARCC manuscript describing scoring method. 2. Review of powerpoint summary of SPARCC method plus completion of SPARCCRETIC module. 3. Re-review of powerpoint summary. B. Same 3-step strategy as A except SPARCCRETIC module completed at stage 3. Participants scored scans from 25 axSpA cases blinded to time point after each stage of training and reliability of scoring was compared to SPARCC developer scores by ICC. Each of the 75 cases that were scored by the 15 readers had 2 time points varying from 3 months to 2 years and each batch of 25 cases had comparable scores for BME and structural lesions when scored by SPARCC developers.

Results: Very good scoring proficiency for status and change scores was evident for SPARCC BME even at stage 1 and even by non-experienced readers with similar levels of reliability irrespective of reader prior expertise with the method (Table). The beneficial impact of the SPARCCRETIC module on scoring proficiency was most consistently evident for the scoring of structural lesions and for Strategy B, where the impact was evident for all structural lesions, level of reader expertise, and status as well as change scores (Figures 1 and 2).

Conclusion: Attaining scoring proficiency for MRI structural lesions in axSpA is difficult but can be consistently improved by using the SPARCCRETIC module, even for experienced readers.

Supporting image 1

Table. Inter-rater reliability (Status/Change ICC) compared to radiologist SPARCC developer

Supporting image 2

Figure 1

Supporting image 3

Figure 2


Disclosures: W. Maksymowych, AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis Limited; A. Hadsbjerg, Novartis; M. Østergaard, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Janssen, Gilead, Novartis, Pfizer, UCB; R. Micheroli, None; S. Pedersen, Novartis, AbbVie/Abbott, UCB, Pfizer, Merck/MSD; A. Ciurea, AbbVie, Novartis, Merck/MSD; N. Vladimirova, Novartis; M. Nissen, AbbVie/Abbott, Pfizer, Amgen, Novartis, Janssen; K. Bubova, None; S. Wichuk, None; M. de Hooge, None; A. Mathew, None; K. Pintaric, None; M. gregova, None; Z. Snoj, None; M. Wetterslev, None; K. Gorican, None; J. Paschke, None; I. Eshed, None; R. Lambert, Calyx, CARE Arthritis, Image Analysis Group.

To cite this abstract in AMA style:

Maksymowych W, Hadsbjerg A, Østergaard M, Micheroli R, Pedersen S, Ciurea A, Vladimirova N, Nissen M, Bubova K, Wichuk S, de Hooge M, Mathew A, Pintaric K, gregova M, Snoj Z, Wetterslev M, Gorican K, Paschke J, Eshed I, Lambert R. Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/validation-of-the-sparccretic-e-tool-for-ensuring-scoring-proficiency-of-mri-lesions-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-sparccretic-e-tool-for-ensuring-scoring-proficiency-of-mri-lesions-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology